Clorox Company (CLX) shares fell Wednesday after the household products giant delivered a mixed bag of second-quarter fiscal 2026 results that left investors wondering about the year ahead.

The Numbers Tell Two Stories

The company posted adjusted earnings per share of $1.39, falling short of the $1.43 analysts were expecting. But revenue came in at $1.673 billion, comfortably beating the $1.64 billion consensus estimate.

Here's where things get interesting. Net sales actually declined 1% year over year on both a reported and organic basis, driven by lower consumption. Gross margin contracted 60 basis points to 43.2%, squeezed by higher manufacturing and logistics costs. Not exactly the kind of report that inspires confidence.

A Tale of Four Segments

The results varied wildly across Clorox's business lines. Health and Wellness saw net sales climb 2% year over year, powered by a 2-point volume increase tied to additional shipments from the final phase of an ERP transition, plus strong performance in Professional Products.

International operations also delivered, with net sales jumping 7% thanks to favorable pricing mix, positive foreign exchange effects, and higher volume.

But the Household segment took a 6% hit year over year, with volume dropping 3 points and price mix delivering another 3-point drag. Lifestyle wasn't much better, falling 5% on decreased volume driven primarily by lower consumption.

The Real Problem: Too Much Stuff in Warehouses

CEO Linda Rendle tried to keep things optimistic, noting that "our second-quarter results were generally in line with our expectations and reflect continued progress against our strategic priorities." She emphasized the company's focus on executing back-half plans supported by innovation and investments, plus excitement around the recently announced GOJO Industries acquisition.

But here's the actual story buried in the outlook: Clorox's fiscal 2026 is being dragged down by what the company describes as a temporary inventory issue rather than weaker demand. Retailers built up about two weeks of extra inventory at the end of fiscal 2025 ahead of an ERP system transition. Now they're sitting on all that extra bleach and cleaning products, which means they're ordering less in 2026.

The math is brutal. The company estimates this inventory correction will slash fiscal 2026 sales growth by about 7.5 percentage points and lower earnings per share by roughly 90 cents. That translates into a 30% decline in diluted EPS and a 23% drop in adjusted EPS compared with fiscal 2025.

Looking Ahead Despite the Headwinds

Despite all this, Clorox reaffirmed its fiscal 2026 adjusted EPS guidance at $5.95 to $6.30, versus consensus of $5.90. The company slightly narrowed its sales guidance to $6.394 billion to $6.678 billion from $6.390 billion to $6.680 billion, compared to consensus expectations of $6.485 billion.

Clorox shares were down 3.11% at $111.40 during premarket trading on Wednesday.